Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.

	Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.
	Ma, Ding ; Gao, Qing-Lei ; Zhu, Jianqing ; Zhao, Weidong ; Huang, Yi ; An, Ruifang ; Zheng, Hong ; Qu, Pengpeng ; Wang, Li ; Zhou, Qi
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2022-06-01
卷号	40
ISSN号	0732-183X
资助项目	AstraZeneca
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000863680303533
资助机构	AstraZeneca
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129849]
专题	中国科学院合肥物质科学研究院
作者单位	1.Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Peoples R China 2.Hunan Canc Hosp, Changsha, Peoples R China 3.Pantai Hosp Kuala Lumpur, Kuala Lumpur, Malaysia 4.Shandong Univ, Qilu Hosp, Jinan, Peoples R China 5.Sichuan Univ, West China Second Univ Hosp, Dept Gynecol & Obstet, Chengdu, Peoples R China 6.Sichuan Univ, West China Second Univ Hosp, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu, Peoples R China 7.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China 8.Liaoning Canc Hosp, Shenyang, Peoples R China 9.Harbin Med Univ, Gynecol Ward 1, Canc Hosp, Harbin, Peoples R China 10.Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Ma, Ding,Gao, Qing-Lei,Zhu, Jianqing,et al. Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Ma, Ding.,Gao, Qing-Lei.,Zhu, Jianqing.,Zhao, Weidong.,Huang, Yi.,...&Zang, Rongyu.(2022).Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Ma, Ding,et al."Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.".JOURNAL OF CLINICAL ONCOLOGY 40(2022).